1. Home
  2. CNVS vs MAIA Comparison

CNVS vs MAIA Comparison

Compare CNVS & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cineverse Corp.

CNVS

Cineverse Corp.

HOLD

Current Price

$2.40

Market Cap

67.1M

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.24

Market Cap

79.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNVS
MAIA
Founded
2000
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Video Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.1M
79.0M
IPO Year
2016
2022

Fundamental Metrics

Financial Performance
Metric
CNVS
MAIA
Price
$2.40
$1.24
Analyst Decision
Buy
Analyst Count
1
0
Target Price
$9.00
N/A
AVG Volume (30 Days)
189.0K
606.5K
Earning Date
02-17-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.33
EPS
N/A
N/A
Revenue
$65,733,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$84.42
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.77
$0.87
52 Week High
$6.25
$3.19

Technical Indicators

Market Signals
Indicator
CNVS
MAIA
Relative Strength Index (RSI) 40.66 38.54
Support Level $2.34 $1.13
Resistance Level $2.65 $1.48
Average True Range (ATR) 0.15 0.07
MACD -0.03 -0.02
Stochastic Oscillator 13.56 4.84

Price Performance

Historical Comparison
CNVS
MAIA

About CNVS Cineverse Corp.

Cineverse Corp is a main streaming technology and entertainment company. Its core business operates as a portfolio of owned and operated streaming channels with enthusiast fan bases; a large-scale aggregator and full-service distributor of feature films and television programs; and a proprietary technology software-as-a-service platform for over-the-top (OTT) app development and content distribution through subscription video-on-demand (SVOD), dedicated ad-supported (AVOD), ad-supported streaming linear (FAST) channels, social video streaming services, and audio podcasts. It generates revenue from streaming and digital, Base distribution, Podcast and other, and Other non-recurring.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: